Nordea Investment Management AB Has $37.81 Million Position in Prestige Consumer Healthcare Inc. $PBH

Nordea Investment Management AB grew its position in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) by 547.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 615,215 shares of the company’s stock after purchasing an additional 520,186 shares during the quarter. Nordea Investment Management AB’s holdings in Prestige Consumer Healthcare were worth $37,811,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in PBH. Allspring Global Investments Holdings LLC increased its stake in shares of Prestige Consumer Healthcare by 4.6% in the third quarter. Allspring Global Investments Holdings LLC now owns 1,592,375 shares of the company’s stock valued at $100,893,000 after buying an additional 70,376 shares during the period. Assenagon Asset Management S.A. acquired a new stake in Prestige Consumer Healthcare during the 3rd quarter worth approximately $1,890,000. Tributary Capital Management LLC boosted its position in Prestige Consumer Healthcare by 157.3% during the 3rd quarter. Tributary Capital Management LLC now owns 379,410 shares of the company’s stock worth $23,675,000 after buying an additional 231,969 shares during the period. JPMorgan Chase & Co. grew its holdings in Prestige Consumer Healthcare by 30.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 459,228 shares of the company’s stock worth $28,656,000 after acquiring an additional 106,224 shares during the last quarter. Finally, Franklin Resources Inc. grew its holdings in Prestige Consumer Healthcare by 51.8% during the 2nd quarter. Franklin Resources Inc. now owns 33,476 shares of the company’s stock worth $2,673,000 after acquiring an additional 11,429 shares during the last quarter. 99.95% of the stock is currently owned by institutional investors.

Insider Activity

In other news, VP Jeffrey Zerillo sold 1,000 shares of the business’s stock in a transaction that occurred on Wednesday, February 11th. The shares were sold at an average price of $65.93, for a total value of $65,930.00. Following the transaction, the vice president owned 41,048 shares in the company, valued at approximately $2,706,294.64. The trade was a 2.38% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 1.40% of the company’s stock.

Prestige Consumer Healthcare Price Performance

Shares of PBH opened at $62.77 on Tuesday. Prestige Consumer Healthcare Inc. has a 1 year low of $57.25 and a 1 year high of $89.37. The company has a debt-to-equity ratio of 0.58, a current ratio of 3.11 and a quick ratio of 1.93. The company has a market capitalization of $2.97 billion, a price-to-earnings ratio of 16.61, a price-to-earnings-growth ratio of 1.92 and a beta of 0.41. The business has a 50-day moving average of $65.77 and a 200-day moving average of $63.24.

Prestige Consumer Healthcare (NYSE:PBH) last posted its quarterly earnings data on Thursday, February 5th. The company reported $1.14 EPS for the quarter, missing analysts’ consensus estimates of $1.16 by ($0.02). Prestige Consumer Healthcare had a return on equity of 12.02% and a net margin of 16.90%.The company had revenue of $283.44 million during the quarter, compared to analyst estimates of $286.93 million. During the same period in the prior year, the firm earned $1.22 earnings per share. Prestige Consumer Healthcare’s revenue was down 2.4% compared to the same quarter last year. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.540 EPS. As a group, equities research analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms have recently issued reports on PBH. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Prestige Consumer Healthcare in a research note on Thursday, January 22nd. Jefferies Financial Group reduced their price objective on shares of Prestige Consumer Healthcare from $70.00 to $66.00 and set a “hold” rating on the stock in a research note on Friday, January 30th. Three research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $76.50.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).